



italfarmacia
LABORATORI

INJECTABLE LINE

DERMORIGENERATIVE BIOSTIMULATION, FILLER



SKINLINE

*Multiple treatment protocols, for every skin type,
but always for a natural result.*

SKIN AGEING IS A MULTIFACTORIAL PROCESS.

Many factors contribute to the appearance of wrinkles, in addition to age: the dermis decreases its capacity to produce collagen, elastin and hyaluronic acid due to the action of ultraviolet rays, smog, stress, pollution, incorrect nutrition, and all those metabolic factors capable of generating free radicals.

Fibroblasts, the cells that produce collagen, elastin, and hyaluronic acid in the dermis, have on their surface and hyaluronic acid, have many receptors on their surface, three of which are particularly interesting because, when stimulated, they induce the fibroblast to produce collagen of different types.

The receptors identified as CD39 and CD40 induce the formation of 1st type collagen (fibrotic collagen) while CD44 induces the formation of 3rd type reticular collagen. **Reticular collagen is characteristic of young skin, the fibrotic one of aged skin.**

A biostimulation (CD44 activation) inducing dermal regeneration with new formation of reticular collagen is only possible with platelet growth factors or with products based on '**hyaluronic acid fragments' in the range of 20 to 38 monomers**, whereas macromolecular hyaluronic acid does not induce any kind of fibroblastic activation, although it can be useful in deep hydration of deep hydration.

SKINLINE



SKIN BIOSTIMULATION LINE, based on fragments of hyaluronic acid (in a range between 20 and 38 monomers) and amino acids, is a treatment that helps maintain the youthfulness of the skin, producing reticular collagen, improving turgidity, elasticity, skin tone and counteracting the action of free radicals.

Skin B[®], Skin Colin[®], Skin OX[®], Skin R[®] produce true **biostimulation** based on the principle of CD44 activation of fibroblasts in order to supply the principles necessary for the cell to build collagen, elastin and glycosaminoglycans, optimizing skin functions and slowing down biological damage.

Exclusive formula based on the careful selection of substances already naturally present in the skin. Very high safety standards: Medical Device Class III, sterile ampoule guaranteeing extreme purity and no risk of bacterial contamination. Diversified and extremely simple treatment protocols.

ALL MEDICAL DEVICES OF THE INJECTABLE BIOSTIMULATION LINE, APPLICABLE ON THE FACE AND BODY, ARE PRODUCED IN OUR FACTORY AND REGISTERED ACCORDING TO THE NEW RDM REGULATION.



SKIN-B[®]

BIOREGENERATING TO PREVENT
AND TREAT SKIN DAMAGE ON THE FACE



SKIN-Colin[®]

MUSCLE BIONIFICANT AND FOR THE
CELL REGROWTH IN THE EPIDERMIS.



SKIN-OX[®]

BIOSTIMULANT AND ANTIOXIDANT TO
COMBAT FREE RADICALS.



SKIN-R[®]

BIOSTIMULANT FOR
MATURE AND LOOSE SKIN.

Four intradermal solutions based on hyaluronic acid fragments, amino acids and 'ad hoc' components capable of stimulating specific skin receptors, improving hydration, elasticity, firmness and skin tone.

SKIN-B®



DEEP BIOREGENERATIVE ACTION TO PREVENT AND TREAT SKIN DAMAGE ON THE FACE.



HYALURONIC ACID + AMINO ACIDS

*Regenerating and modelling solution for the dermal matrix containing **hyaluronic acid fragments** and **amino acids** capable of stimulating CD44 receptors and activating fibroblasts with formation of hyaluronic acid, collagen and elastin.*

COMPOSITION

Hyaluronic acid, Isoleucine, Leucine, Lysine, Proline, Valine, Glycine, Serine, Alanine, Cysteine, Phosphate buffer system, Water p.p.i.



TREATMENT PROTOCOL

The most widely used medical procedure to optimize the physiology of the skin is **biostimulation**, involving fibroblastic activation aimed at the neoformation of matrix components and a normalization of its colloidal state.

The medical device used contains:

Hyaluronic acid fragments (20-38 monomers) capable of activating CD44 of the fibroblast.

Amino acid precursors of collagen, elastin and glycosaminoglycans. The biological optimization of the skin's condition is thus achieved.

SKIN B® can be combined with all the other biostimulants: **SKIN R®**, **SKIN-COLIN®**, **SKIN-OX®** and injected all over the face.



ONE OF MULTIPLE TREATMENTS

1 session every 7 days for 4 times;
1 session every 15 days for 2 times.




MAINTENANCE

1 session every 30 days.

1. Glabella - 2. Cheekbones - 3. Nasogenial folds
4. Lower corner of the mouth

After 4 sessions of SKIN-B®



SKIN-OX[®]



BIOSTIMULANT AND ANTIOXIDANT AGAINST FREE RADICALS.




HYALURONIC ACID + AMINO ACIDS + REDUCED GLUTATHIONE + VITAMIN C

*Biostimulating and antioxidant solution for the dermal matrix containing **hyaluronic acid fragments** and **amino acids** capable of stimulating CD44 receptors and activating fibroblasts with formation of hyaluronic acid, collagen and elastin. The presence of reduced glutathione and vitamin C helps prevent and counteract free radical damage.*

COMPOSITION

Hyaluronic acid, Serine, Alanine, Cysteine, Leucine, Lysine, Proline, Valine, Glycine, Reduced glutathione, Sodium ascorbyl phosphate, Phosphate buffer system, Water p.p.i.



TREATMENT PROTOCOL

The **SKIN biostimulation procedure** aims to optimize the physiology of the skin by means of fibroblastic activation for the neoformation of matrix components and a normalization of the colloidal state of the matrix as well as preventing chrono-aging damage caused by oxygen free radicals.

The Medical Device used contains:

Hyaluronic acid fragments (20-38 monomers) capable of activating CD44 in the fibroblast.

Amino acid precursors of collagen, elastin and glycosaminoglycans. Biological optimization of the skin's condition is thus achieved.

Antioxidants to block oxygen free radical damage. The only one to contain two 'drugs' applicable according to the new MDR regulation.



Combining SKIN-OX® and SKIN-Colin® results in a more pronounced anti-photo effect.



ONE OF MULTIPLE TREATMENTS

Brightness: 1 session every 30 days.

Skin lightening: 1 session every 7 days for 1 month.

Photo & Chrono-Ageing: 1 session every 7 days for 1 month.

After 1 cycle of SKIN-OX®



1. Face - 2. Neck - 3. Hands - 4. Décolleté

SKIN-Colin®



REGULATION OF CELL REGROWTH IN THE EPIDERMIS AND MUSCLE TONING.




HYALURONIC ACID + AMINO ACIDS + CHOLINE

*Solution regulating epidermal cell regrowth and stimulating muscle tone containing **hyaluronic acid fragments** and amino acids capable of stimulating CD44 receptors and activating fibroblasts with formation of new hyaluronic acid, collagen and elastin. **Choline**, the precursor of acetyl choline, has a toning effect on the skin.*

COMPOSITION

Hyaluronic acid, Choline, Glycine, Serine, Alanine, Proline, Lysine, Cysteine, Sodium chloride, Phosphate buffer system, Water p.p.i.



TREATMENT PROTOCOL

The **SKIN biostimulation procedure** aims to optimize the physiology of the skin through fibroblastic activation for the neoformation of matrix components and a normalization of the colloidal state of the matrix, as well as preventing photoaging damage to the epidermis.

The Medical Device used contains:

Hyaluronic acid fragments (20-38 monomers) capable of activating CD44 in the fibroblast.

Amino acid precursors of collagen, elastin and glycosaminoglycans. Biological optimization of the skin's condition is achieved.

Choline as a precursor of skin acetylcholine has a toning effect, optimizing the skin's cholinergic system and corneocyte differentiation with prevention of UV damage.



Combining SKIN-OX® and SKIN-Colin® results in a more pronounced anti-photo effect.






ONE OF MULTIPLE TREATMENTS

Face: 1 session every 15-30 days, alone or combined with SKIN-OX® for oxidized skin.



Body toning: 15 ml for each muscle (i.m.), once a week for 4 times.

After 3 cycles of SKIN-COLIN®



1. Face - 2. Abdomen

SKIN-R®



DEEP BIOREGENERATIVE AND BIOSTIMULATING ACTION TO PREVENT AND TREAT SKIN DAMAGE ON FACE.




HYALURONIC ACID + AMINO ACIDS

Skin toning solution containing a hypertonic, hyperosmolar solution of hyaluronic acid and amino acids capable of inducing the formation of fibrotic collagen.

COMPOSITION

Hyaluronic acid, Proline, Lysine, Glycine, Proline, Sodium chloride, Phosphate buffer system, Water p.p.i.



TREATMENT PROTOCOL

Biorestructuring involves the activation of the fibrotic fibroblast subpopulation in order to increase the rigidity of the dermis with scar collagen deposition (type I)

The Medical Device used contains:

Hyaluronic acid fragments (20-38 monomers) capable of attracting CD44 from the fibroblast.

A hypertonic acid solution capable of inducing an irritative response and stimulating fibrotic fibroblasts.

Collagen precursor amino acids. Amino acids enable the formation of fibrotic collagen (type I). The result is fibrosis of the dermis with distension of the skin tissue

Treatment is carried out on hypotonic tissues (face, neck, décolleté, buttocks, thigh, arm, epigastric area).



ONE OF MULTIPLE TREATMENTS

Aged skin: 1 session every 15 days, 4 times. Wait 2 months, then repeat the cycle 3 times.





Very aged skin: 1 session every 7 days, for 4-6 sessions.

1. Neck - 2. Décolleté

THE FACELIFT WITHOUT A SCALPEL

After 4 sessions of SKIN-R®



SOME OF THE MANY TREATMENTS THAT CAN BE CARRIED OUT WITH THE SKIN LINE

BIOBOTULINOTM



To optimise a natural result

BOTULINUM TOXIN, COMBINED WITH SKIN-B® OR SKIN-OX®, ALLOWS INCREASED COLLAGEN PRODUCTION AND SEBUM REGULATION.

Botulinum toxin causes an increase in fibroblastic activity in vitro. The increase in type I collagen production is significant as early as 36 hours after exposure to the toxin. Botulinum toxin is capable of modifying the viscoelastic properties of facial skin.

Prof. M. BASSO - Master Lecturer in Aesthetic Medicine University La Sapienza Rome

Prof. E. DI LELLA - Master Lecturer in Aesthetic Medicine University La Sapienza Rome

PHASE 1 (day 0): BIOBOTULIN (cocktail)

PHASE 2 (day 15, 30, 60 from phase 1): RESTRUCTURING BIOSTIMULATION

PATIENTS GLOGAU 1-3

1ST DILUTION:

Vistabex or Bocuture or Leytbo 50 U in 1 ml physiological saline
Azalure or Alluzience 125 U in 1 ml physiological saline

2ND DILUTION:

Vistabex or Bocuture or Leytbo 50 U in 5 ml biostimulant cocktail
Azalure or Alluzience 125 U in 5 ml biostimulant cocktail
MATERIALS
3 ml syringes, 30G needles 4 or 12 mm, Nanosoft® needle

PATIENTS GLOGAU 4

1ST DILUTION:

Vistabex or Bocuture or Leytbo 50 U in 1 ml biostimulant cocktail
Azalure or Alluzience 125 U in 1 ml biostimulant cocktail

2ND DILUTION:

Vistabex or Bocuture or Leytbo 50 U in the remaining 4 ml of biostimulant cocktail
Azalure or Alluzience 125 U in the remaining 4 ml of biostimulant cocktail
MATERIALS
3 ml syringes, 30G needles 4 or 12 mm, Nanosoft® needle

TREATMENT PROTOCOL

3 TREATMENT CYCLES PER YEAR



INTRADERMAL POINT BY POINT TECHNIQUE (0.05 ML/POINT), ON FOREHEAD, EYE CONTOUR, CHEEKS, JAW PROFILE, NECK, DÉCOLLETÉ, INNER ARMS, ABDOMEN, KNEES, INNER THIGH.

Syringes 3 ml - Needles 32 G 4 or 12 mm



BOTULINONEEDLING™



Biostimulation 'without puncture'

COUNTERACTING THE SIGNS OF AGEING ON THE SKIN WITH A SOFT PROCEDURE

Botulinoneedling™

is a procedure that, without the use of syringes, acts on the skin at various levels through a medical device that microperforates the skin, opening the way for active ingredients that exert a specific action at various levels. The microtrauma caused by the needling action activates the natural process of tissue regeneration and renewal.

It is a technique that allows a mixture of botulinum toxin, hyaluronic acid, amino acids, vitamins and antioxidants to penetrate the skin without the use of syringes.

Microneedling

Microperforation technique of the outer layers of the skin, which activates skin regeneration processes and induces the formation of new collagen and elastin.

Most of the active ingredients used in aesthetic treatments are mostly of hydrophilic nature and therefore have difficulty in penetrating the skin barrier; hence the need for needling. With needling, the corneal barrier is made permeable and even large molecules can penetrate through this layer without causing trauma and bruising.

Combining botulinum toxin with a biostimulating solution

Botulinum toxin is used to reduce the muscular component of wrinkle formation by relaxing muscle fibres that insert superficially into the dermis, reducing the wrinkled effect of the skin.

Botulinum toxin also acts on the sebum production of the pilosebaceous glands; thus, it can positively affect oily or acne-prone skin. It also acts on the formation of new collagen by reducing the activity of metalloproteinases.

What we use

- A medical device which, depending on the need, can be a roller or a plunger on which micro-needles (maximum length 0.75 mm) are
- assembled, a mixture obtained by mixing bovine toxin with a product containing hyaluronic acid fragments, amino acids and antioxidants, **Skin-B®** or **Skin-Ox®**.


The protocol involves a series of four sessions approximately at a distance of 15 days apart.

In the first session, botulinum toxin is combined with the treatment; in the following three sessions, at 15, 30 and 45 days, microneedling and **Skin-B®** will be used.

The protocol involves two cycles per year and can be performed in any season.

Prof. G. FERRARELLI - Adjunct Professor La Sapienza University Rome; Director Master's Degree in Aesthetic and Bioregenerative Medicine Unicamillus University.

TREATMENT PROTOCOL



TREATMENT PROTOCOL

- T1** Thorough skin cleansing and disinfection, microneedling step (may be preceded by application of local anaesthetic cream). A solution obtained by diluting 50UM/125US of BTX A with 5ml of HAAM solution is evenly applied to the skin; wait for the product to penetrate, massaging gently until dry.
- T2** After 15 days microneedling session with the same procedure, using HAAM without BTX.
- T3** After 15 days microneedling session with the same procedure, using HAAM without BTX.
- T4** After 15 days microneedling session with the same procedure, using HAAM without BTX.



HOME TREATMENTS



SKIN-B[®]
EVOLUTION CREAM


Biostimulant, compacts and evens out the skin; biostimulation aid with SKIN-B[®]



SKIN-Colin[®]
EVOLUTION CREAM

Biostimulating, plumping, adjuvant biostimulation with SKIN-Colin[®]

HOME TREATMENTS



SKIN-OX[®]
EVOLUTION CREAM

*Antioxidant, anti-wrinkle,
immediate brightener,
biostimulation aid with SKIN-OX[®]*



SKIN-R[®]
EVOLUTION CREAM

*Lifting, toning, firming, adjuvant
of bio-restructuring with SKIN-R[®]*

SKIN-F®

CROSS-LINKED HYALURONIC
ACID, GLYCINE, PROLINE



FOR HER FOR HIM

Skin-F® fillers, the newest product addition to the SKIN line family, are produced by Italfarmacia, a company specialized in the production of medical devices for the aesthetic medicine, with 30 years of experience.



SKIN-F® FILLERS CORRECT FACIAL BLEMISHES, RESTORE VOLUMES, THUS RESHAPING THE PROFILE AND FILLING WRINKLES AND FROWS, RESTORING HYDRATION, TONE AND ELASTICITY TO THE SKIN.

The quality of **hyaluronic acid**, the sophisticated **cross-linking** and the presence of **Glycine** and **Proline** (dermostructuring amino acids) make **SKIN-F® fillers** a perfect gel, with mechanical properties similar to those of the extracellular matrix, with optimal density and viscosity. The dual dermostructuring and skin stretching action allow a natural and uniform result over time.



SKIN-F®



3 DOSAGES FOR SPECIFIC WOMAN NEEDS

SKIN-F® 22

FOR SUPERFICIAL CONTOURING

Superficial, perioral, periocular lines



SKIN-F® 24

RESTORATION OF VOLUMETRIC

DEFICITS OF MEDIUM DEPTH

Cheekbones, lips, nasolabial folds,
marionette lines






SKIN-F® 26

VOLUME RESTORATION

Cheeks, cheekbones, chin,
mandibular area, nose.



**RESULT OF SKIN-F®
BEFORE AND AFTER
TREATMENT**





SKIN-F[®] MAN

3 DOSAGES FOR SPECIFIC MAN NEEDS

SKIN-F[®] MAN 22

FOR SUPERFICIAL CONTOURING

Superficial, perioral, periocular lines



SKIN-F[®] MAN 24

RESTORATION OF VOLUMETRIC

DEFICITS OF MEDIUM DEPTH

Cheekbones, lips, nasolabial folds,
marionette lines




SKIN-F[®] MAN 26

VOLUME RESTORATION

Cheeks, cheekbones, chin,
mandibular area, nose.



**RESULT OF SKIN-F[®]
BEFORE AND AFTER
TREATMENT**





BASIC INFORMATION

COMPOSITION	SKIN-F® 22 SKIN-F® 24 SKIN-F® 26	HA 22 mg/ml HA 24 mg/ml HA 26 mg/ml
VOLUME		1 ml
PH		6,5 - 7,5
OSMOLALITY		260-340 mOsm/kg
BACTERIAL ENDOTOXINS		0,05 EU/ml
NEEDLES	SKIN-F® 22 SKIN-F® 24 SKIN-F® 26	27 G - 13 mm 25 - 27 G - 16 mm - 13 mm 25 G - 16 mm
DURABILITY		On average 6 months depending on skin conditions and patient's lifestyle.

RHEOLOGY

VISCOUS MODULE G' [Pa]	SKIN-F® 22 SKIN-F® 24 SKIN-F® 26	58,68 71,57 123,9
VISCOUS MODULE G'' [Pa]	SKIN-F® 22 SKIN-F® 24 SKIN-F® 26	28,31 36,30 57,14
TANGENT	SKIN-F® 22 SKIN-F® 24 SKIN-F® 26	0,53 0,51 0,46

VISCOSITY

ELASTIC MODULE G' [Pa]	SKIN-F® 22 SKIN-F® 24 SKIN-F® 26	308,49 446,20 655,72
ELASTIC MODULE G'' [Pa]	SKIN-F® 22 SKIN-F® 24 SKIN-F® 26	167,70 240,75 358,12
TANGENT	SKIN-F® 22 SKIN-F® 24 SKIN-F® 26	12,11 17,51 25,86

SKIN-F® MAN



BASIC INFORMATION

COMPOSITION	SKIN-F® MAN 22 SKIN-F® MAN 24 SKIN-F® MAN 26	HA 22 mg/ml HA 24 mg/ml HA 26 mg/ml
VOLUME		1 ml
PH		6,5 - 7,5
OSMOLALITY		260-340 mOsm/kg
BACTERIAL ENDOTOXINS		0,05 EU/ml
NEEDLES	SKIN-F® MAN 22 SKIN-F® MAN 24 SKIN-F® MAN 26	27 G - 13 mm 25 - 27 G - 16 mm - 13 mm 25 G - 16 mm
DURABILITY		On average 6 months depending on skin conditions and patient's lifestyle.

RHEOLOGY

VISCOUS MODULE G' [Pa]	SKIN-F® MAN 22 SKIN-F® MAN 24 SKIN-F® MAN 26	61,60 74,43 127,62
VISCOUS MODULE G'' [Pa]	SKIN-F® MAN 22 SKIN-F® MAN 24 SKIN-F® MAN 26	29,73 37,75 58,85
TANGENT	SKIN-F® MAN 22 SKIN-F® MAN 24 SKIN-F® MAN 26	0,50 0,49 0,44

VISCOSITY

ELASTIC MODULE G' [Pa]	SKIN-F® MAN 22 SKIN-F® MAN 24 SKIN-F® MAN 26	323,91 464,05 675,39
ELASTIC MODULE G'' [Pa]	SKIN-F® MAN 22 SKIN-F® MAN 24 SKIN-F® MAN 26	176,09 250,38 368,86
TANGENT	SKIN-F® MAN 22 SKIN-F® MAN 24 SKIN-F® MAN 26	12,72 18,21 26,64

SKIN LIPS

MOISTURIZING LIPGLOSS WITH HELICHRYSUM SEED OIL FOR **POSTFILLER** TREATMENT.

SKIN LIPS is a lipgloss based on shea butter, helichrysum seed oil and vitamin E, used after filler treatment.

SKIN LIPS, thanks to its active ingredients, allows the lips stay supple, making them softer and moist. Besides the presence of helichrysum seed oil makes the **Skin Lips** particularly suitable in the treatment of labial herpes simplex.



BIBLIOGRAPHICAL SOURCES

THE ROLE OF HYALURONIC ACID AND AMINO ACID AGAINST THE AGING OF THE HUMAN SKIN: A CLINICAL AND HISTOLOGICAL STUDY. Antonio Scarano, Andrea Sbarbati, Roberto Amore, Eugenio Luigi Iorio, Giuseppe Ferraro, Marco Marchetti, Domenico Amuso. Journal of Comestic Dermatology, July 2021.

EVALUATION OF THE EFFICACY AND SAFETY OF HYALURONIC ACID AND SUPPLEMENTED WITH AMINO ACIDS, AND GLUTATHIONE OR COLIN, FOR THE PREVENTION AND TREATMENT OF WRINKLES ON THE FACE, NECK, DÉCOLLETÉ AND HANDS. Svolacchia F, Svolacchia L, Marchetti M, Prisco C, Inchingolo F, Amuso D, Giuzio F, Scarano A. Eur Rev Med Pharmacol Sci. 2023

A CLINICAL INVESTIGATION OF HYALURONIC ACID FORTIFIED WITH AMINO ACIDS FOR ADDRESSING FACIAL AGING. Scarano A, A. Sbarbati, R Amore, E.L. Iorio, G. Ferraro, M. Marchetti, D. Amuso and S.R. Tari European Journal of Musculoskeletal Diseases ISSN 2975-044X/2024.

REPORT OF THE SAFETY ASSESSMENT OF HYALURONIC ACID, POTASSIUM HYALURONATE, AND SODIUM HYALURONATE. Becker, L. C. et al. Final Int. J. Toxicol. 28, 5-67 (2009).

CUTANEOUS TISSUE REPAIR: BASIC BIOLOGIC CONSIDERATIONS I. Clark, R. A. F. J. Am. Acad. Dermatol. 13, 701-725 (1985).

HYALURONAN AND WOUND HEALING: A NEW PERSPECTIVE. Burd, D. A. R. et al. Br. J. Plast. Surg. 44, 579-584 (1991).

THE AGEING DERMIS: THE MAIN CAUSE FOR THE APPEARANCE OF 'OLD' SKIN. CM, L. Br. J. Dermatol. 122 Suppl 35, 5-11 (1990).

HYALURONIC ACID IN CUTANEOUS INTRINSIC AGING. I, G., T, L., G, C., C, G. & G, D. Int. J. Dermatol. 33, 119- 122 (1994).

EVIDENCE FOR STRUCTURAL CHANGES IN DERMATAN SULFATE AND HYALURONIC ACID WITH AGING. MO, L., CS, R. & XY, H. Carbohydr. Res. 159, 127-136 (1987).

ACQUIRED AMINO ACID DEFICIENCIES: A FOCUS ON ARGININE AND GLUTAMINE. Morris, C. R., Hamilton-Reeves, J., Martindale, R. G., Sarav, M. & Ochoa Gautier, J. B Nutr. Clin. Pract. 32, 305-475 (2017).

HYALURONIC ACID HYDROGELS FOR BIOMEDICAL APPLICATIONS. JA, B. & GD, P. Adv. Mater. 23, (2011).

HYALURONIC ACID: A NATURAL BIOPOLYMER WITH A BROAD RANGE OF BIOMEDICAL AND INDUSTRIAL APPLICATIONS. G, K., L, S., R, S. & P, G. Biotechnol. Lett. 29, 17-25 (2007).

HYALURONIC ACID (HYALURONAN): A REVIEW. Necas, J., Bartosikova, L., Brauner, P. & Kolar, J. Vet. Med. (Praha). 53, 397-411 (2008).

SKIN ANTI-AGING STRATEGIES. R, G., AI, L., A, T., E, M. & CC, Z. Dermatoendocrinol. 4, (2012).

THE HYALURONIC ACID FILLERS. CURRENT UNDERSTANDING OF THE TISSUE DEVICE INTERFACE. Greene, J. J. & Sidle, D. M. Facial Plastic Surgery Clinics of North America vol. 23 423-432 (2015).

FILLERS: FROM THE PAST TO THE FUTURE. Glogau, R. G. Seminars in Cutaneous Medicine and Surgery vol. 31 78-87 (2012).

COMPARATIVE PHYSICAL PROPERTIES OF HYALURONIC ACID DERMAL FILLERS. Kablik, J., Monheit, G. D., Yu, L. P., Chang, G. & Gershkovich, J. Dermatologic Surg. 35, 302-312 (2009).

ADVANCES IN FACIAL REJUVENATION: BOTULINUM TOXIN TYPE A, HYALURONIC ACID DERMAL FILLERS, AND COMBINATION THERAPIES - CONSENSUS RECOMMENDATIONS. Carruthers, J. D. A. et al. Plastic and Reconstructive Surgery vol. 121 (2008).

NATIVE HYALURONSÄURE IN DER ÄSTHETISCHEN MEDIZIN - ERGEBNISSE EINER EXPERTENKONFERENZ. JDDG - Wiest, L. & Kerscher, M. Journal of the German Society of Dermatology vol. 6 176-180 (2008).

HAUTE AUTORITÉ DE SANTÉ -Publications institutionnelles. https://www.has-sante.fr/jcms/c_1267546/fr/publications-institutionnelles.

ADVERSE REACTIONS TO DERMAL FILLERS: A REVIEW OF EUROPEAN EXPERIENCES. Andre, P., Lowe, N. J., Parc, A., Clerici, T. H. & Zimmermann, U. Journal of Cosmetic and Laser Therapy vol. 7 171-176 (2005).

THE ROLE OF HYALURONIC ACID AND AMINO ACID AGAINST THE AGING OF THE HUMAN SKIN: A CLINICAL AND HISTOLOGICAL STUDY Scarano A, Sbarbati A, Amore R, Iorio EL, Ferraro G, Marchetti M, Amuso D PMID: 33090687 DOI: 10.1111/jocd.13811.

HYALURONIC ACID FILLERS IN LIP AUGMENTATION PROCEDURE: A CLINICAL AND Scarano A, Puglia F, Cassese R, Mordente I, Amore R, Ferraro G, Sbarbati A, Lo Russo F, Greco Lucchina A, Amuso D HISTOLOGICAL STUDY J Biol Regul Homeost Agents 2019 Nov-Dec; 33(6 Suppl. 2):103-108.

INJECTABLE FILLERS: REVIEW OF MATERIAL AND PROPERTIES Attenello NH, Maas CS. Facial Plast Surg 31, 29, 2015.

INTRODUCTION TO FILLERS Carruthers J, Carruthers A, Humphrey S. Plast Reconstr Surg 136, 120S, 2015.

BIOPHYSICAL CHARACTERISTICS OF HYALURONIC ACID SOFT-TISSUE FILLERS AND THEIR RELEVANCE TO AESTHETIC APPLICATIONS. Sundaram H, Cassuto D. Plast Reconstr Surg 132, 5S, 2013.

COMPARATIVE PHYSICAL PROPERTIES OF HYALURONIC ACID DERMAL FILLERS Kablik J, Monheit GD, Yu L, Chang G and Gersh- kovich J Dermatol Surg 35, Suppl 1: 302, 2009.

HYALURONIC ACID FILLERS IN FACIAL REJUVENATION Lupo, MP. Semin Cutan Med Surg 25, 122, 2006.

DYNAMICS OF HYALURONIC ACID FILLERS FORMULATED TO MAINTAIN NATURAL FACIAL EXPRESSION Solish N, Bertucci V, Percec I, Wagner T, Nogueira A, Mashburn J. Cosmet Dermatol. 2019. Jun;18(3):738-746. doi: 10.1111/jocd.12961. Epub 2019 Apr 29.

DYNAMIC ASSESSMENT OF HYALURONIC ACID FILLERS THAT ADAPT TO FACIAL MOVEMENT. Percec I, Bertucci V, Solish N, Wagner T, Nogueira A, Mashburn J An Objective, Quantitative, Plast Reconstr Surg. 2020 Feb;145(2):295e-305e. doi: 10.1097/PRS.00000000000006461.

ASSESSMENT OF THE EFFICACY AND SAFETY OF HYALURONIC ACID GEL INJECTION IN THE RESTORATION OF FULLNESS OF THE UPPER LIPS Yazdanparast T, Samadi A, Hasanazadeh H, Nasrollahi SA, Firooz A, Kashani MN J Cutan Aesthet Surg. 2017 Apr-Jun;10(2):101-105. doi: 10.4103/JCAS. JCAS_115_16.

EVALUATION OF THE RESULTS OF INJECTABLE HYALURONIC ACID FILLERS FOR THE FACE Matecka M, Lelonkiewicz M, Pieczyńska A, Pawlaczky M Subjective Clin Interv Aging. 2020 Jan 13;15:39-45. doi: 10.2147/ CIA.S233405. eCollection 2020.

A HYALURONIC ACID FILLERS WITH COHESIVE POLYDENSIFIED MATRIX FOR SOFT-TISSUE AUGMENTATION AND REJUVENATION: A LITERATURE REVIEW Prasetyo AD, Prager W, Rubin MG, Moretti EA, Nikolis Clin Cosmet Investig Dermatol. 2016 Sep 8;9:257-80. doi: 10.2147/CCID.S106551. e Collection 2016.